Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study

Gupta, Aditya K.; Alexis, Mercy; Raboobee, Noufal; Hofstader, S. L. R.; Lynde, C.W.; Adam, Paul; Summerbell, Richard C.; Doncker, P. De

doi:10.1046/j.1365-2133.1997.18141912.x

Cited by 56 publications

(48 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, all 9 non-responders had this dermatophyte, suggesti ng that the durati on of therapy has to be extended beyond 2 weeks in certain cases of T. rubrum infecti on. Although the number of cases resulti ng from other pathogens was small, they do respond to this short-term therapy with drug usually in Tenia capiti s. [6][7][8][9][10][11][12][13] Bothitraconazole and terbinafi ne are highly lipophilic and kerati nophilic. They persist in the stratum corneum and hair in high concentrati ons for 3-4 weeks aft er therapy is disconti nued.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Shakya

Jha

Dangol

et al. 2013

Med. J. Shree Birendra Hosp.

View full text Add to dashboard Cite

Introducti on: Tenia Cruris is the commonest dermatophyte infecti on which is common in men and aggravated by warm humid conditi on Teniarubrum is the main species for the disease 1,2 . Itraconazole and Terbinafi ne are the bett er newer drugs for the therapeuti c opti on due to their effi cacy, convenient and less side eff ect. Itraconazole is a wider spectrum Thiazole group of fungistati c drugs which inhibit sterol 14 α demethylase impairing biosynthesis of fungal ergosterol. Similarly Terbinafi ne is broad specturmallylamine group of fungicidal acti vity which inhibits squalene 2, 3 epoxidase enzyme thus inhibit fungal biosynsthesis of ergosterol [3][4][5] . These two drugs have been needed conventi onally as a pulse and conti nuous therapy. The main aim of this study is to compare the effi cacy of both drugs and to recommend the eff ecti ve treatment in case of Teniacruris. Methods:In this randomized comparati ve study, the effi cacy and safety of oral itraconazole (n=35) and terbinafi ne (n=35), each given for 2weeks, was compared in pati ents with ti neacruris within the period of 1 year study. Results:The fi nal evaluati on at week 4 showed a cure rate of 91.4% for itraconazole and 82.9% for terbinafi ne. No defi nite adverse eff ect was noted. Conclusions:Itraconazolehas high cure rate and less failure rate without side eff ects in comparision toTerbinafi ne.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Shakya

Jha

Dangol

et al. 2013

Med. J. Shree Birendra Hosp.

View full text Add to dashboard Cite

show abstract

“…In the case of itraconazole treatments, only one study has shown that, for most dermatophytes, the sensitivity in vitro could be correlated to those in vivo [21]. In a retrospective study, T. violaceum (2 cases), T. soudanense (1 case), T. tonsurans (6 cases) and M. gypseum (1 case) in tinea capitis were shown to respond to itraconazole pulse therapy [8]. …”

Section: Discussionmentioning

confidence: 99%

“…A double-blind comparative study with griseofulvin revealed that the two drugs had similar efficacy but there was a better tolerance for itraconazole [5]. Other studies have confirmed the high efficacy and tolerability of itraconazole in tinea capitis [6, 7, 8]. Terbinafine belongs to the allylamine class of antifungals that also inhibit the synthesis of ergosterol but at a different stage in the synthesis pathway as the azole compounds; it inhibits the squalene epoxidase, an enzyme that catalyzes the conversion of squalene to squalene 2,3-epoxide.…”

Section: Introductionmentioning

confidence: 98%

Tinea capitis Dermatophytes: Susceptibility to Antifungal Drugs Tested in vitro and in vivo

et al. 1998

View full text Add to dashboard Cite

Background: Tinea capitis is a worldwide-spread infection of the scalp caused by dermatophytes and is predominantly seen in children. The clinical manifestations range from mild scaling lesions to widespread alopecia or highly inflammatory suppurating lesions. Terbinafine and itraconazole seem to be promising therapies with shorter treatment durations than griseofulvin. Objective: The objective of the present study was to test the sensitivity of different species of dermatophytes towards terbinafine and itraconazole, and to compare the results with a retrospective study on 35 immunocompetent patients with tinea capitis who were treated with terbinafine (Lamisil^®). Methods: Minimal inhibitory concentrations (MIC) were measured with an agar dilution method. Results: Each tested species of dermatophyte was sensitive to terbinafine and itraconazole at different concentration ranges. The MIC for terbinafine ranged from 0.005 to 0.5 μg/ml and for itraconazole from 40 to 80 μg/ml. Microsporum canis was the dermatophyte least sensitive to terbinafine. Our retrospective study showed that the cure rate was excellent for Trichophyton violaceum and T. soudanense, variable for T. mentagrophytes and poor for M. canis and M. langeronii. Conclusions: (i) Regarding the results of susceptibility tests obtained with species involved in tinea capitis, clinical efficacy is not related to MIC measured in vitro; (ii) identification of the isolated dermatophyte from tinea capitis seems to be important for choosing the appropriate treatment.

show abstract

“…With M. canis tinea capitis a duration of 4 -6 weeks may be required. The number of pulses required for treatment is in part dependent upon the severity of the tinea capitis [259,262,263]. The number of pulses required for treatment is in part dependent upon the severity of the tinea capitis [259,262,263].…”

Section: Ef Cacymentioning

confidence: 99%

Tinea capitis

2000

View full text Add to dashboard Cite

Tinea capitis is a common dermatophyte infection of the scalp in children. Dermatophytes are classified into three genera; tinea capitis is caused predominantly by Trichophyton or Microsporum species. On the basis of host preference and natural habitat, dermatophytes are also classified as anthropophilic, geophilic and zoophilic. The etiological agents of tinea capitis usually fall in the first and last categories. In North America, tinea capitis is now predominantly due to Trichophyton tonsurans. During the past 100 years the most common North American organism for tinea capitis was initially Microsporum canis followed later by M. audouinii. In other parts of the world the epidemiology varies. Tinea capitis is generally observed in children over the age of 6 years and before puberty, with African Americans being the most affected group. Clinical presentations are seborrheic-like scale, 'black dot' pattern, inflammatory tinea capitis with kerion and tiny pustules in the scalp. The clinical diagnosis should be confirmed by mycological examination. Wood's light examination was of value in diagnosing tinea capitis due to M. canis and M. audouinii; however, it is not helpful in T. tonsurans tinea capitis. Asymptomatic carriers may be a significant reservoir of infection and spread of spores may also involve inanimate objects. Carriers may benefit from shampooing their hair. Treatment of tinea capitis requires an oral antifungal agent. The data from the use of terbinafine, itraconazole and fluconazole are promising and suggest that these agents have an efficacy similar to griseofulvin while shortening the duration of therapy. Both griseofulvin and the newer antimycotics have a favorable adverse-effect profile and are associated with high compliance.

show abstract

Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study

Cited by 56 publications

References 16 publications

Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Tinea capitis Dermatophytes: Susceptibility to Antifungal Drugs Tested in vitro and in vivo

Tinea capitis

Contact Info

Product

Resources

About